コンテンツへスキップ
Merck

HCVD2MAG-67K

MILLIPLEX® Human Cardiovascular Disease Panel

Configurable Human CVD 10-Plex Panel 2

別名:

CVD assay snapshot, CVD multiplex product sheet, cardiovascular biomarker listing, cardiovascular biomarker profile, coagulation and inflammation detection kit, human CVD assay overview, human cardiovascular panel summary, human cardiovascular research tool, human vascular biomarker info, vascular inflammation biomarker panel

ログインで組織・契約価格をご覧ください。

この商品について

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000


製品名

MILLIPLEX® Human Cardiovascular Disease Panel,

Quality Level

description

Configurable Human CVD 10-Plex Panel 2

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

plasma
cell culture supernatant(s)

assay range

accuracy: 88%
(Myoglobin), accuracy: 90%
(P-selectin), accuracy: 98%
(GDF-15), standard curve range: 0.0005-2.5 ng/mL
(GDF-15), standard curve range: 0.012-50 ng/mL
(Lipocalcin-2/NGAL), standard curve range: 0.024-100 ng/mL
(Myoglobin & MPO), standard curve range: 0.085-350 ng/mL
(sICAM-1), standard curve range: 0.122-500 ng/mL
(sVCAM-1), standard curve range: 0.244-1,000 ng/mL
(D-dimer, SAA & P-selectin), standard curve range: 1.221-5,000 ng/mL
(ADAMTS 13), inter-assay cv: <20%
intra-assay cv: <15%

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Cardiovascular disease is closely linked to inflammation, endothelial dysfunction, oxidative stress, and coagulation abnormalities. This set of biomarkers—ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, and sVCAM-1—captures key indicators of vascular injury, immune activation, and thrombotic risk. These analytes are widely studied in the context of atherosclerosis, acute coronary syndromes, and systemic inflammation, making them highly relevant for translational and clinical cardiovascular research.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 10 analytes in human serum, plasma, or cell culture supernatants.

Analytes included: ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, sVCAM-1Note: D-Dimer cannot be measured in plasma samples.

Assay Characteristics: Refer to assay protocol for details on cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

Features:
  • Targets biomarkers involved in vascular inflammation, endothelial activation, and coagulation
  • Includes 10 analytes relevant to cardiovascular risk, oxidative stress, and immune response
  • Multiplex format enables simultaneous detection from minimal sample volume
  • Compatible with human serum and plasma samples
  • Designed for research in atherosclerosis, thrombosis, acute coronary syndromes, and systemic inflammation
Benefits:
  • Provides a comprehensive profile of cardiovascular and inflammatory biomarkers
  • Supports investigation of vascular injury, immune activation, and thrombotic mechanisms
  • Facilitates evaluation of therapeutic interventions and biomarker-based risk assessment
  • Enables high-throughput analysis with reduced sample and reagent use
  • Delivers reproducible, sensitive results for translational and clinical research

Legal Information

Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


Still not finding the right product?

Explore all of our products under


pictograms

Exclamation markEnvironment

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

保管分類

10 - Combustible liquids

wgk

WGK 3


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Please refer to KIT Component information

pdsc

Please refer to KIT Component information

prtr

Please refer to KIT Component information

fsl

Please refer to KIT Component information

ishl_indicated

Please refer to KIT Component information

ishl_notified

Please refer to KIT Component information

cart

キットコンポーネントの情報を参照してください

jan



試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする


関連コンテンツ

Learn about biomarkers of cardiovascular disease (CVD) and discover how multiplex CVD panels, such as MILLIPLEX® multiplex assays, are being used to increase the efficiency of biomarker discovery for CVD research.

Uncover tips and tricks to multiplexing in this guide from the experts. Learn how you can enhance the power of your research with MILLIPLEX® multiplexing, including industry guidance for immunoassays, multiplexing tips, one-day MILLIPLEX® multiplex assays for limited lab time, and more.

心血管疾患(CVD)バイオマーカーの詳細を確認し、MILLIPLEX® マルチプレックスアッセイのようなマルチプレックスCVDパネルを用いて、CVD研究のバイオマーカー探索の効率を高める方法をご覧ください。

すべての関連コンテンツを見る

Alberto Soriano-Maldonado et al.
Journal of clinical medicine, 7(12) (2018-11-28)
This study assessed the effect of 12-week aerobic exercise on arterial stiffness (primary outcome), inflammation, oxidative stress, and cardiorespiratory fitness (secondary outcomes) in women with systemic lupus erythematosus (SLE). In a non-randomized clinical trial, 58 women with SLE were assigned
Lilliam Rocha-Penha et al.
Hypertension (Dallas, Tex. : 1979), 69(6), 1173-1180 (2017-05-04)
Elevated levels of myeloperoxidase have been demonstrated in women with preeclampsia where it may contribute to endothelial dysfunction mediated, in part, by nitric oxide impairment. In this study, we investigated myeloperoxidase in hypertensive disorders of pregnancy and its contribution to
Estefania Simoes et al.
International journal of obesity (2005), 45(4), 879-887 (2021-02-03)
Childhood overweight and obesity are a global concern, with prevalence rising dramatically over the last decades. The condition is caused by an increase in energy intake and reduction of physical activity, leading to excessive fat accumulation, followed by systemic chronic